An ophthalmology expert provides an overview of biosimilars and their potential in ophthalmology practices.
Utilization of Biosimilars in Retinal Diseases
Dr Peter Kaiser outlines approval process of biosimilars and highlights key differences from approval process of reference products.
Dr Kaiser shares critical differences in primary outcome readout in clinical studies for biosimilars vs reference products for retinal diseases.
Dr Peter Kaiser provides an overview of biosimilars that are either approved or are being developed for treatment of retinal diseases.
An ophthalmologist discusses challenges and concerns that physicians might face when using biosimilars for retinal diseases.
Dr Peter Kaiser shares helpful hints for patient communication and for including biosimilars in clinical practice.
Advertisement
Advertisement
Trending on HCPLive
1
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD
2
Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS
3
Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape?
4
New Nonsteroidal Options Are Reshaping Pediatric Atopic Dermatitis Care
5